Cabozantinib in Progressive Medullary Thyroid Cancer


ABSTRACT

Cabozaentinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clinical activity in patients with medullary thyroid cancer (MTC) in phase I.

Patients and Methods
We conducted a double-blind, phase III trial comparing cabozantinib with placebo in 330 patients with documented radiographic progression of metastatic MTC. Patients were randomly assigned (2:1) to cabozantinib (140 mg per day) or placebo. The primary end point was progression-free survival (PFS). Additional outcome measures included tumor response rate, overall survival, and safety.

Results
The estimated median PFS was 11.2 months for cabozantinib versus 4.0 months for placebo (hazard ratio, 0.28; 95% CI, 0.19 to 0.40; P < .001). Prolonged PFS with cabozantinib was observed across all subgroups including by age, prior TKI treatment, and RET mutation status (hereditary or sporadic). Response rate was 28% for cabozantinib and 0% for placebo; responses were seen regardless of RET mutation status. Kaplan-Meier estimates of patients alive and progression-free at 1 year are 47.3% for cabozantinib and 7.2% for placebo. Common cabozantinib-associated adverse events included diarrhea, palmar-plantar erythrodysesthesia, decreased weight and appetite, nausea, and fatigue and resulted in dose reductions in 79% and holds in 65% of patients. Adverse events led to treatment discontinuation in 16% of cabozantinib-treated patients and in 8% of placebo-treated patients.

Conclusion
Cabozantinib (140 mg per day) achieved a statistically significant improvement of PFS in patients with progressive metastatic MTC and represents an important new treatment option for patients with this rare disease. This dose of cabozantinib was associated with significant but manageable toxicity.

INTRODUCTION

Medullary thyroid cancer (MTC) is a rare malignancy originating from calcitonin-producing parafollicular C cells of the thyroid. The majority (approximately 75%) of cases occur sporadically, and the remaining arise as part of three inherited autosomal dominant syndromes: multiple endocrine neoplasia 2A (MEN2A), MEN2B, or familial MTC. Germline mutations in the gene encoding the tyrosine kinase receptor rearranged during transfection (RET) are present in almost all patients with inherited MTC, and somatic mutations are found in approximately 65% of patients with sporadic MTC. The activating point mutation M918T, representing approximately 80% of somatic RET mutations and 95% of MEN2B cases, is an indicator for poor prognosis. In addition to RET, the hepatocyte growth factor receptor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2) signaling pathways are upregulated in thyroid tumors and have been implicated in the pathogenesis of MTC through promotion of proinvasive and proangiogenic phenotypes.

Whereas complete surgical resection is curative for some patients with MTC, patients with distant metastases have a short median survival time, although progression rates are variable. Serum levels of calcitonin and carcinoembryonic antigen (CEA) are important indicators of tumor burden.
and prognosis. Cytotoxic chemotherapy or radiotherapy have limited, transient activity in patients with unresectable or metastatic MTC. Although the tyrosine kinase inhibitor (TKI) vandetanib has limited, transient activity in patients with unresectable or metastatic MTC, it has not been extensively examined in patients with documented radiographic disease progression at baseline.

Cabozantinib is a TKI that targets three relevant pathways in MTC: MET, VEGFR2, and RET. In a phase I study, cabozantinib demonstrated promising clinical activity in a cohort of heavily pretreated patients with MTC. We report here the results of an international, double-blind, randomized, placebo-controlled phase III study evaluating cabozantinib in patients with metastatic MTC and documented radiographic disease progression at study entry.

**PATIENTS AND METHODS**

*Eligibility Requirements*  
Eligible patients were adults with histologically confirmed, unresectable, locally advanced, or metastatic MTC. Patients were required to have radiographic disease progression per modified Response Evaluation Criteria in Solid Tumors (mRECIST) guidelines at screening compared with an image obtained within the prior 14 months. Documentation of progressive disease (PD) to establish eligibility was by independent review in 89.4% of patients, and by investigator assessment in the remaining patients. Exclusion criteria included prior systemic anticancer therapy within 4 weeks or significant cardiac, hematopoietic, hepatic, or renal dysfunction. There was no limit on prior therapy, including exposure to other TKIs. All patients provided written informed consent. The protocol was approved by ethics committees or institutional review boards at each clinical site, nationally, or both.

*Randomization and Treatments*  
Patients were randomly assigned in a 2:1 ratio to receive cabozantinib or placebo in a double-blind fashion and were stratified by age (≤ 65 years, > 65 years) and prior TKI treatment (yes, no). Patients received 140 mg (freebase equivalent) of cabozantinib or placebo capsules orally once per day until either intolerable toxicity or disease progression per mRECIST occurred. Dose holds and up to two dose-level reductions (to a minimum dose of 60 mg per day) were allowed. The study remained blinded until the primary analysis of progression-free survival (PFS) and the interim analysis of overall survival (OS) were complete. Patients receiving placebo were not permitted to cross over to cabozantinib.

*Efficacy*  
The primary end point was duration of PFS. Key secondary end points included OS and objective response rate (ORR). The database cutoff date for all planned analyses was June 15, 2011, except for the primary PFS analysis, which was April 6, 2011 (when the 138th and 139th independent radiology review committee [IRC] -determined PFS events occurred). Radiographic tumor assessments were performed every 12 weeks (± 5 days) from random assignment until PD, using mRECIST. Tumor assessments were performed by a blinded IRC to determine response and/or progression for the primary efficacy analyses. PFS was calculated as the time from random assignment to the earlier of documented PD per mRECIST or death.

*Biomarker Measurements*  
Methods for determining RET mutational status and changes in calcitonin and CEA are provided in the Data Supplement. Tumor and blood samples collected at screening were analyzed for RET mutation; for a sample to be considered negative for RET mutation, the complete sequence for exons 10, 11, and 13 to 16 must have been obtained and been free of mutation.

*Safety*  
Safety assessments included monitoring adverse events (AEs), performing standard laboratory tests (hematology, serum chemistry, and urinalysis) and physical examinations, and recording ECGs. Severity of AEs was assessed by using the National Cancer Institute’s Common Terminology Criteria for Adverse Events, version 3.0. Serious AEs (SAEs) were defined in accordance with the International Conference on Harmonisation Guidelines for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting, Topic E2A.

**RESULTS**

*Patients*  
From September 2008 through February 2011, 330 patients from 23 countries were randomly assigned 2:1 to receive cabozantinib (219 patients) or placebo (111 patients; Fig 1). Baseline characteristics in the treatment groups were well balanced (Table 1). Forty percent of patients (n = 133) had received prior anticancer therapy, and 21% (n = 68) received prior TKI treatment. Twenty-five percent had two or more systemic therapies (24% cabozantinib; 28% placebo). Most patients (285 [86%]) had sporadic disease. Approximately half the patients (48.2%; n = 159) were RET mutation–positive, 12% (n = 41) were RET mutation–negative, and 39% (n = 130) had unknown RET mutation status due to missing sequence data or to the presence of a mutation of unknown significance. M918T was the predominant RET mutation (74%; 118 of 159 patients with documented mutations). The main sites of disease in the majority of patients included lymph nodes, liver, lung, and bone.

*Treatment*  
At the database cutoff date, 45% (98 of 219) of patients in the cabozantinib arm and 14% (15 of 111) of patients in the placebo arm were receiving study treatment. The arithmetic median duration of exposure was 204 days for cabozantinib-treated patients (interquartile range, 99 to 392 days), almost twice that of placebo-treated patients (median 105 days; interquartile range, 83 to 170 days). Because of the large percentage of patients receiving treatment at data cutoff, the median duration of exposure is an underestimate in the cabozantinib treatment group. The median time of follow-up was 13.9 months (range, 3.6 to 32.5 months).

*PFS*  
The study met its primary end point of demonstrating improvement in PFS as determined by the IRC (Fig 2A). Cabozantinib treatment led to a substantial improvement in PFS compared with placebo.
Estimated median PFS duration was 11.2 months in the cabozantinib group and 4.0 months in the placebo group. The stratified HR was 0.28 (95% CI, 0.19 to 0.40; \( P < .001 \)). A tabulation of censoring reasons is provided in the Data Supplement. Similar results were obtained in analyses of PFS as determined by investigator (\( 13.8 - 0.28 \) (95% CI, 0.19 to 0.40; group and 4.0 months in the placebo group. The stratified HR was 0.47 (44%) of the 217 patient deaths required for the final analysis. In this analysis, no statistically significant difference between treatment arms was observed (HR, 0.98; 95% CI, 0.63 to 1.52). Survival follow-up is planned to continue until at least 217 deaths have been observed.

Calcitonin and CEA

Calcitonin and CEA response at week 12 was evaluable in 140 (64%) and 170 (78%) cabozantinib-treated patients and 61 (55%) and 71 (64%) placebo-treated patients, respectively. The most common reasons patients were not evaluable were the lack of a week-12 assessment or a calcitonin assay change between the baseline and week-12 assessments (details are provided in the Data Supplement). At baseline, the mean value and standard deviation (SD) for calcitonin in the cabozantinib and placebo arms were 6,370 pmol/L (SD, 11,332 pmol/L) and 8,846 pmol/L (SD, 15,722 pmol/L), respectively (Welsh’s \( t \) test \( P = .27 \)). For CEA, the mean values for cabozantinib and placebo arms were 736 \( \mu \)g/L (SD, 3,555 \( \mu \)g/L) and 1,108 \( \mu \)g/L (SD, 5,168 \( \mu \)g/L), respectively (Welsh’s \( t \) test \( P = .58 \)). These baseline values were judged to be not meaningfully different. From baseline to week 12, the cabozantinib arm displayed significant decreases in calcitonin (mean, \(-45.2\% \) [SD, 60.71%]) compared with increases in the placebo arm (\(+57.3\% \) [SD, 115.4%], \( P < .001 \)). Changes in CEA levels from baseline to week 12 showed a similar trend (\(-23.7\% \) [SD, 58.21%] in the cabozantinib arm \( v \) +88.7% [SD, 182.8%] in the placebo arm; \( P < .001 \). A generally linear relationship was observed when changes in calcitonin and CEA from baseline to week 12 (up to approximately 200% increases) were compared with changes in target lesion size (Fig 3).

Safety and Tolerability

AEs reported in \( \geq 10\% \) of cabozantinib-treated patients are summarized in Table 2. Grade 3 or 4 AEs were reported in 69% (148 of 214) and 33% (36 of 109) of patients in the cabozantinib and placebo groups, respectively. In cabozantinib-treated patients, the most frequently reported grade 3 or 4 AEs were diarrhea (15.9%), palmar-plantar erythrodysesthesia (12.6%), and fatigue (9.3%). AEs typically
associated with vascular endothelial growth factor (VEGF) pathway inhibition, including hypertension, hemorrhage, fistula formation, and GI perforation, occurred more frequently among cabozantinib-treated patients (Table 3).

Laboratory abnormalities with a higher incidence in the cabozantinib arm (between arm difference of ≥ 5% at all grades or ≥ 2% grade 3 to 4) consisted of increased AST, increased ALT, increased alkaline phosphatase, hypocalcemia, hypophosphatemia, hyperbilirubinemia, hypomagnesemia, hypokalemia, hypnatremia, lymphopenia, neutropenia, and thrombocytopenia (Data Supplement). There was no drug-induced severe liver injury. Thyroid-stimulating hormone (TSH) level above normal was noted after treatment initiation in 57% of cabozantinib patients compared with 19% of placebo patients.

AEs were generally managed with concomitant medications, dose interruptions, and dose reductions; 79% (169 of 214) of cabozantinib-treated patients and 9% (10 of 109) of placebo patients had dose reductions. Sixty-five percent (140 of 214) of cabozantinib-treated patients and 17% (19 of 109) of placebo patients had dose interruptions due to AEs. AEs were listed as the primary reason for treatment discontinuation in 16% (35 of 214) of cabozantinib-treated patients and in 8% (nine of 109) of placebo-treated patients. In addition, 6% (12 of 214) of the patients in the cabozantinib arm discontinued treatment for reasons other than PD, AE, or death; 11 of these patients had ongoing AEs at the time of treatment discontinuation, although AEs were not reported as the primary reason for treatment discontinuation in these patients.

SAEs were more frequent in cabozantinib- versus placebo-treated patients (42.1% [90 of 214] vs 22.9% [25 of 109]). SAEs that occurred at a ≥ 2% frequency in cabozantinib- versus placebo-treated patients included mucosal inflammation (2.8% [six of 214] vs 0% [zero of 109]), hypocalcemia (2.8% [six of 214] vs 0% [zero of 109]), pulmonary embolism (2.3% [five of 214] vs 0% [zero of 109]), and hypertension (2.3% [five of 214] vs 0% [zero of 109]). At the planned interim analysis the overall death rate was balanced between the two treatment arms. Ninety-six deaths were reported: 65 (30%) in the cabozantinib group and 30 (28%) in the placebo group, and one patient who did not receive study drug. Most deaths were attributed to disease progression (77% [50 of 65] in the cabozantinib arm and 80% [24 of 30] in the placebo arm).

Grade 5 AEs occurring within 30 days of last dose were reported in 7.9% of cabozantinib-treated patients and 7.3% of placebo-treated patients. Grade 5 AEs on the cabozantinib arm consisted of fistula (three patients, including one patient with concurrent pneumonia, all related), respiratory failure (two patients, one related), hemorrhage (two patients, one related), multiorgan failure (two patients, none related), and sepsis (not related), sepsis/multiorgan failure (related), sudden death (related), hepatic failure (not related), cardiopulmonary failure (related), pneumonia (not related), general physical health deterioration (not related), and death not otherwise specified (related) in one patient each. Grade 5 AEs on the placebo arm consisted of dysphagia (not related), cardiopulmonary failure (deemed related), shock (likely septic shock, not related), acute respiratory distress syndrome (not related), pneumonia (not related), pneumonia/general physical health deterioration (deemed related), hepatic failure (not related), and asthma (not related) in one patient each. Some of the grade 5 AEs in both treatment arms were reported in patients whose primary cause of death was reported as PD.

Patients with progressive MTC have limited treatment options. Cabozantinib was associated with an improvement in estimated PFS compared with placebo in a patient population with documented
progressive MTC, with an increase of more than 7 months in estimated median PFS compared with placebo, and a confirmed response rate of 28%. Importantly, benefit from the use of cabozantinib was observed across multiple sensitivity and subgroup analyses, including prior TKI or systemic therapy, the presence of bone metastases, and in all RET mutation subgroups analyzed.

This study is one of the largest conducted in patients with MTC. To the best of our knowledge, it is the first randomized phase III trial in a population of patients with MTC rigorously defined with PD per mRECIST within a defined time period (14 months) required at study entry. This population with advanced disease had a short estimated median PFS of 4.0 months and a high rate of morbidity reported as AEs in the placebo arm. The poor prognosis of patients enrolled onto the cabozantinib study is in contrast to the patient population studied in the vandetanib phase III trial, in which PD per mRECIST was not required at study entry, and for which the estimated median PFS in the placebo arm was 19.3 months. This suggests that the patient population studied in the vandetanib trial had relatively indolent disease.
and confirms that patients who were enrolled onto the cabozantanib study were in significant need of therapy.

At the planned interim analysis for OS, no statistically significant difference between treatment arms was observed. The final analysis of survival will be conducted after 217 events have occurred. This study could offer a unique opportunity to explore a relationship between PFS and OS in MTC.

Recent research has suggested that RET inhibition can lead to early changes in calcitonin levels independent of changes in tumor size, but in this study, correlations were observed between changes in both calcitonin and CEA from baseline to week 12 and changes in target lesion size, suggesting that these serum markers may be predictive of patient benefit.

The most frequent grade 3 or 4 AEs were diarrhea, palmar-plantar erythrodysesthesia, and fatigue, generally consistent with those seen in studies with VEGF pathway inhibitors, with other TKIs, and with prior experience in open-label cabozantanib studies.

Gastrointestinal perforations, fistula development, and hemorrhage occurred in the cabozantanib arm of this study. These potentially life-threatening AEs have previously been observed with VEGF pathway inhibition and require caution, especially when treating patients who are at risk for such events. We did not observe clinically relevant QTcF prolongation of more than 500 milliseconds, as was encountered in the vandetanib phase III trial.
Metabolic changes reported in the cabozantinib arm included increased TSH and hypocalcemia. Increased TSH has been reported during treatment with other TKIs, and is possibly a result of increased type 3 deiodinase activity. Notably, most of the study patients had a prior thyroidectomy and were receiving thyroid hormone and calcium supplementation at baseline.

AEs were managed with supportive care and with dose reductions and holds allowing for patients to remain on treatment for extended periods of time, which is similar to what has been observed with other TKIs. However, the rate of holds and reductions due to AEs was high, and evaluation of a lower starting dose of cabozantinib versus 140 mg in patients with progressive, metastatic MTC is planned.

Cabozantinib treatment substantially improves PFS and response rates and has a manageable AE profile in patients with progressive metastatic MTC, including those previously treated with TKIs. Cabozantinib has been approved by the US Food and Drug Administration for the treatment of patients with progressive, metastatic MTC and represents an important new therapeutic option for patients with this rare malignancy.

### Table 3. AEs Associated With VEGF Pathway Inhibition

<table>
<thead>
<tr>
<th>AE</th>
<th>Cabozantinib (n = 214)</th>
<th>Placebo (n = 109)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All Grades</td>
<td>Grade ≥ 3</td>
</tr>
<tr>
<td>Hypertension</td>
<td>70</td>
<td>32.7</td>
</tr>
<tr>
<td>Venous thrombosis</td>
<td>12</td>
<td>5.6</td>
</tr>
<tr>
<td>GI perforation</td>
<td>7</td>
<td>3.3</td>
</tr>
<tr>
<td>GI fistula</td>
<td>2</td>
<td>0.9</td>
</tr>
<tr>
<td>Abdominal/pelvic abscess</td>
<td>5</td>
<td>2.3</td>
</tr>
<tr>
<td>Non-GI fistula</td>
<td>8</td>
<td>3.7</td>
</tr>
<tr>
<td>Arterial thrombosis</td>
<td>5</td>
<td>2.3</td>
</tr>
<tr>
<td>Proteinuria</td>
<td>4</td>
<td>1.9</td>
</tr>
<tr>
<td>Wound complication</td>
<td>4</td>
<td>1.9</td>
</tr>
<tr>
<td>Osteonecrosis</td>
<td>3</td>
<td>1.4</td>
</tr>
<tr>
<td>RPLS</td>
<td>1</td>
<td>0.5</td>
</tr>
</tbody>
</table>

### REFERENCES

15. Cassinelli G, Favini E, Degl’Innocenti D, et al: RET/PTC1-driven neoplastic transformation and...


27. Schöffski P, Elisei R, Müller S, et al: An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. J Clin Oncol 30:358s, 2012 (suppl; abstr 5508)


Acknowledgment

We thank the clinical sites for providing care for the study participants; the members of the independent safety data monitoring committee (Christopher Nutting, Ralph D’Agostino, Bruce Brockstein, and Christian Nasr); Douglas Clary, Margaret Tonda, Steven Milwee, Frauke Bentzien, Milan Mangeshkar, and Charlotte Furey (Exelixis) for their help with data management and analysis; and Gisela Schwab and Dana Aftab (Exelixis) for their critical review of the manuscript.